C1GALT1, or Core 1 β1,3-galactosyltransferase, plays a pivotal role in the biosynthesis of the core 1 structure of O-glycans, which are fundamental components of the glycoprotein biosynthesis process. This enzyme catalyzes the transfer of galactose from UDP-Galactose to N-acetylgalactosamine (GalNAc)-residues on mucin-type glycoproteins, a key step in the synthesis of mucin-type O-glycans. These glycoproteins are not only essential for cell-cell communication but also for the stabilization of extracellular matrices, modulation of immune responses, and facilitation of signal transduction processes. Given its central role in cellular functions and the maintenance of cellular integrity, C1GALT1's activity is closely regulated within the cell, and its dysregulation has been associated with various pathophysiological states, including but not limited to, disruptions in immune recognition and cancer progression. The enzyme's activity, therefore, represents a critical point of interest for understanding cellular glycosylation processes and their impact on broader biological systems.
The inhibition of C1GALT1, whether direct or indirect, involves the modulation of this enzyme's activity or the alteration of its substrate availability, leading to significant impacts on the glycosylation patterns of proteins. Indirect inhibitors primarily target upstream processes or related pathways that contribute to the enzyme's substrate pool or its enzymatic activity. For instance, interfering with the biosynthesis of dolichol-linked oligosaccharides or the processing of N-glycans can lead to a reduced availability of properly folded glycoproteins, which in turn affects the substrate availability for C1GALT1. Similarly, disrupting the function of the Golgi apparatus or the endoplasmic reticulum, where much of the glycosylation process including that catalyzed by C1GALT1 occurs, can indirectly modulate the enzyme's activity. These mechanisms highlight the complexity of cellular glycosylation and the intricate balance of enzymatic activities required for proper protein function. As such, understanding the pathways and processes that indirectly influence C1GALT1 activity offers insights into the broader regulatory mechanisms governing protein glycosylation and opens avenues for exploring the modulation of this crucial biological process.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Tunicamycin | 11089-65-9 | sc-3506A sc-3506 | 5 mg 10 mg | $172.00 $305.00 | 66 | |
Tunicamycin inhibits N-linked glycosylation by blocking the formation of dolichol-linked oligosaccharides. This disruption in glycosylation can indirectly affect C1GALT1's substrate availability, potentially reducing its activity. | ||||||
Swainsonine | 72741-87-8 | sc-201362 sc-201362C sc-201362A sc-201362D sc-201362B | 1 mg 2 mg 5 mg 10 mg 25 mg | $138.00 $251.00 $631.00 $815.00 $1832.00 | 6 | |
Swainsonine inhibits mannosidase II, an enzyme involved in processing N-glycans, which may lead to altered glycoprotein synthesis. This alteration could indirectly influence C1GALT1 activity by modifying its glycoprotein substrates. | ||||||
Castanospermine | 79831-76-8 | sc-201358 sc-201358A | 100 mg 500 mg | $184.00 $632.00 | 10 | |
An inhibitor of glucosidase I and II, castanospermine affects N-glycan trimming in the ER and Golgi, potentially leading to misfolded glycoproteins. This may indirectly reduce C1GALT1's functional glycoprotein substrates. | ||||||
Deoxynojirimycin | 19130-96-2 | sc-201369 sc-201369A | 1 mg 5 mg | $73.00 $145.00 | ||
As a glucosidase inhibitor, deoxynojirimycin impacts the processing of N-glycans, possibly leading to a buildup of improperly glycosylated proteins. This could indirectly limit C1GALT1 substrate availability. | ||||||
Kifunensine | 109944-15-2 | sc-201364 sc-201364A sc-201364B sc-201364C | 1 mg 5 mg 10 mg 100 mg | $135.00 $540.00 $1025.00 $6248.00 | 25 | |
Kifunensine, a mannosidase I inhibitor, prevents the trimming of high mannose N-glycans, potentially altering glycoprotein structures. This indirect effect could impact C1GALT1 activity by changing its glycoprotein substrates. | ||||||
Brefeldin A | 20350-15-6 | sc-200861C sc-200861 sc-200861A sc-200861B | 1 mg 5 mg 25 mg 100 mg | $31.00 $53.00 $124.00 $374.00 | 25 | |
By disrupting Golgi apparatus function, Brefeldin A inhibits protein transport and secretion. This broad disruption can indirectly affect C1GALT1 by altering the glycosylation and trafficking of its substrates. | ||||||
Celgosivir | 121104-96-9 | sc-488385 sc-488385A sc-488385B | 5 mg 25 mg 100 mg | $525.00 $902.00 $2700.00 | ||
Celgosivir, a prodrug of castanospermine, inhibits glucosidase I, impacting glycoprotein folding and N-glycan maturation. This may indirectly reduce C1GALT1 activity by affecting its glycoprotein substrates. | ||||||
Salubrinal | 405060-95-9 | sc-202332 sc-202332A | 1 mg 5 mg | $34.00 $104.00 | 87 | |
A selective inhibitor of eIF2α dephosphorylation, Salubrinal can indirectly affect glycoprotein synthesis and folding, potentially impacting C1GALT1's substrate availability through ER stress responses. | ||||||
PF-429242 | 947303-87-9 | sc-507498 | 5 mg | $176.00 | ||
By inhibiting S1P (site 1 protease), PF-429242 disrupts the activation of SREBP, which is involved in lipid biosynthesis. This indirect action could influence glycosylation pathways and thus C1GALT1 activity. | ||||||